Form 4: Amphastar Director Sells Shares Under 10b5-1 Plan

Amphastar Pharmaceuticals Director Floyd F. Petersen sold 500 shares of common stock for a weighted average price of $25.2662 per share under a pre-arranged trading plan.

Summary

• Floyd F. Petersen, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), reported a sale of common stock.
• The transaction involved the disposition of 500 shares of common stock.
• The shares were sold at a weighted average price of $25.2662 per share.
• The sale was executed on November 3, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Petersen on November 26, 2024.
• Following this transaction, Mr. Petersen directly beneficially owns 75,531 shares of Amphastar Pharmaceuticals common stock.
• The shares were sold in multiple transactions with prices ranging from $25.00 to $25.47, inclusive.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale of 500 shares by a director, while an insider transaction, was conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new, negative information about the company. The volume is also relatively small compared to the director's remaining holdings.

Negatives

• A director's sale of shares, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although the small volume and 10b5-1 plan mitigate this.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A minor reduction in director ownership, but the pre-planned nature of the sale under Rule 10b5-1 mitigates concerns about its implications for company performance or outlook.

Key Dates

Recommendation

The reported transaction is a small, pre-planned sale by a director under a Rule 10b5-1 plan. Such transactions are generally for personal financial planning and do not typically signal a change in the company's fundamental prospects or warrant a shift in investment recommendation. The director retains a significant holding, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this specific filing does not provide new information to alter the existing investment thesis.

Keywords

Amphastar Pharmaceuticals, AMPH, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan